What is Sustainable Joint Procurement? And how can joint procurement bring benefits to the consolidated procurement body and can it help biosimilar market sustainability? There are certain specifics associated with the joint procurement (JP) development and implementation in Europe.
Topics covered in the article “Sustainable Joint Procurement, Part One”
Experience with JP in Europe
At the National level, Cross-border JP and Organizational experience, and why Europe does not lack organizational expertise.
Dive deeper to understand different tendering authorities.
See why the aggregate knowledge will be critical not only when procuring innovative treatments but also can help create sustainable procurement environment for products that have competition.
Topics covered in the article “Sustainable Joint Procurement, Part Two”
Focus on the institutional dimension and how institutions can shape the market. ” Correspondingly, tendering and contracting mechanisms for biological products in Europe should factor in an acceptable level for business risk biological manufacturers can bear. Just a few weeks after the new SPC Manufacturing waiver has been voted by the Council, a major player in the European biosimilars marketplace announced that they would sell their biologic products manufacturing plant in Hillerød (DK) to FujiFilm… “
Consolidated procurement in the case of biosimilar products sustainability. “At prima vista, it’s a win-win situation – manufacturers win a good deal it can forecast, and the tendering authority realizes more savings at one go…”
The future share of biosimilar products
sustainable joint procurement and will the favored by many procurement authorities’ “winner-takes-all” national level tenders withstand the long run sustainability test?
Update on Brexit concerns on pharmaceuticals sustainable joint procurement. “As noted above, the UK has also signed the JPA…”